stockrow
Friday 6 November 2026
Export IDXX’s income statement to Excel — free account
IDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
669.01
29.54
−4.23%
Follow IDXX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
51.33 | 38.39 | 53.85 | 50.00 | 75.34 | 73.40 | 52.65 | 42.96 | 52.60 | 47.42 |
Piotroski F-Score |
8 | 6 | 8 | 5 | 8 | 7 | 8 | 8 | 9 | 7 |
P/S ratio |
12.64 | 8.75 | 12.43 | 10.08 | 17.45 | 15.76 | 9.34 | 7.30 | 7.03 | 5.94 |
Altman Z-Score |
24.09 | 16.75 | 19.92 | 13.66 | 23.62 | 19.16 | 11.65 | 9.74 | 7.24 | 6.19 |
P/FCF ratio |
56.88 | 47.28 | 59.64 | 88.38 | 88.83 | 78.94 | 75.78 | 58.79 | 46.70 | 38.49 |
Altman Z″-Score (non-manufacturers) |
10.43 | 9.23 | 8.68 | 6.45 | 7.41 | 6.90 | 4.82 | 4.12 | 2.99 | 2.24 |
Beneish M-Score |
(2.50) | (2.48) | (2.38) | (2.22) | (2.29) | (2.42) | (2.37) | (2.31) | (2.64) | (2.76) |
P/Operating CF |
152.94 | 130.12 | 182.09 | 195.77 | 267.19 | 194.85 | 144.69 | 119.12 | 114.35 | 104.73 |
P/B ratio |
33.89 | 21.37 | 30.65 | 55.77 | 81.31 | 67.42 | 126.46 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
50.31 | 31.61 | 44.00 | 227.45 | 242.22 | 126.62 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
12.71 | 8.83 | 12.49 | 10.28 | 17.67 | 15.95 | 9.72 | 7.52 | 7.10 | 6.06 |
EV/EBITDA |
36.33 | 27.36 | 37.74 | 34.24 | 54.80 | 54.63 | 36.51 | 28.96 | 28.19 | 25.05 |
EV/Operating CF |
46.27 | 37.06 | 50.46 | 63.74 | 75.19 | 66.64 | 50.96 | 41.58 | 37.47 | 31.73 |
EV/FCF |
57.16 | 47.74 | 59.95 | 90.09 | 89.94 | 79.91 | 78.85 | 60.54 | 47.16 | 39.23 |
Quick Ratio |
0.64 | 0.71 | 0.96 | 0.42 | 0.67 | 1.23 | 0.50 | 0.48 | 0.70 | 0.64 |
Current Ratio |
1.23 | 1.31 | 1.57 | 0.89 | 1.25 | 1.82 | 0.94 | 0.85 | 0.97 | 0.90 |
Net Debt/EBITDA |
0.18 | 0.26 | 0.20 | 0.65 | 0.68 | 0.66 | 1.42 | 1.53 | 1.59 | 1.89 |
Debt/Assets |
13.42% | 18.75% | 21.41% | 28.01% | 34.88% | 39.59% | 54.73% | 65.07% | 73.60% | 78.66% |
Debt/Equity |
0.28 | 0.39 | 0.47 | 1.26 | 1.23 | 1.44 | 5.64 | (108.34) | (23.42) | (11.13) |
Asset Turnover |
1.30 | 1.19 | 1.22 | 1.30 | 1.36 | 1.31 | 1.43 | 1.36 | 1.21 | 1.18 |
Operating CF/Net income |
1.12 | 1.05 | 1.07 | 0.80 | 1.01 | 1.11 | 1.07 | 1.06 | 1.42 | 1.53 |
Capex/Depreciation |
(0.95) | (1.01) | (1.16) | (1.42) | (1.14) | (1.12) | (1.76) | (1.48) | (0.92) | (0.82) |
Interest Coverage |
35.01 | 36.16 | 26.39 | 22.55 | 31.27 | 20.97 | 17.80 | 14.14 | 11.10 | 10.93 |
| 66.20% | 57.66% | 80.74% | 104.58% | 112.62% | 143.54% | 507.40% | (1,195.50%) | (324.76%) | (231.05%) | |
| 31.89% | 27.10% | 28.14% | 26.20% | 31.48% | 28.19% | 25.39% | 23.20% | 16.22% | 14.77% | |
ROIC |
45.33% | 36.64% | 39.67% | 44.39% | 41.74% | 37.51% | 31.69% | 35.41% | 35.11% | 31.09% |
Return on Tangible Assets |
104.65% | 84.95% | 67.83% | 131.82% | 95.52% | 56.20% | 87.62% | 117.46% | 75.94% | 82.72% |
Average Days of Receivables |
46.85 | 44.35 | 45.61 | 43.43 | 41.81 | 44.69 | 40.84 | 41.04 | 43.49 | 42.04 |
Research and Development Expense of Revenue |
5.84% | 5.64% | 5.22% | 7.57% | 5.01% | 5.22% | 5.53% | 5.33% | 5.54% | 5.70% |
Selling, General and Administrative Expense of Revenue |
24.36% | 26.45% | 24.64% | 25.26% | 24.77% | 27.17% | 28.23% | 28.57% | 29.21% | 29.52% |
Intangible Assets out of Total Assets |
0.16 | 0.16 | 0.14 | 0.17 | 0.19 | 0.13 | 0.16 | 0.17 | 0.14 | 0.15 |
Share Based Compensation of Revenue |
1.39% | 1.55% | 1.63% | 1.48% | 1.17% | 1.14% | 1.63% | 1.14% | 1.19% | 1.12% |
Graham Net Nets |
(0.01) | (0.01) | (0.01) | (0.03) | (0.01) | (0.01) | (0.04) | (0.06) | (0.06) | (0.08) |
Graham Number |
76.94 | 68.47 | 63.95 | 36.47 | 39.91 | 33.71 | 15.18 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
1.95% | 2.60% | 1.86% | 2.00% | 1.33% | 1.36% | 1.90% | 2.33% | 1.90% | 2.11% |
Free Cash Flow Yield |
1.76% | 2.11% | 1.68% | 1.13% | 1.13% | 1.27% | 1.32% | 1.70% | 2.14% | 2.60% |
Revenue per Share |
53.51 | 47.26 | 44.07 | 40.27 | 37.74 | 31.72 | 27.95 | 25.48 | 22.43 | 19.79 |
Operating CF per Share |
14.69 | 11.27 | 10.91 | 6.49 | 8.87 | 7.59 | 5.33 | 4.61 | 4.25 | 3.78 |
Capex per Share |
(1.72) | (1.59) | (1.61) | (1.90) | (1.40) | (1.26) | (1.80) | (1.42) | (0.87) | (0.72) |
Free Cash Flow per Share |
12.98 | 9.68 | 9.30 | 4.59 | 7.46 | 6.33 | 3.53 | 3.19 | 3.38 | 3.06 |
Cash per Share |
2.24 | 3.50 | 5.46 | 1.35 | 1.70 | 4.50 | 1.05 | 1.43 | 5.38 | 4.37 |
Shareholders Equity per Share |
19.96 | 19.34 | 17.87 | 7.28 | 8.10 | 7.41 | 2.07 | (0.11) | (0.61) | (1.21) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
19.96 | 19.34 | 17.87 | 7.28 | 8.10 | 7.41 | 2.07 | (0.11) | (0.61) | (1.21) |
Free Cash Flow |
1,043.58 | 798.08 | 772.88 | 384.15 | 636.00 | 540.44 | 303.93 | 277.15 | 296.57 | 274.16 |
Working Capital |
265.01 | 331.98 | 543.71 | (134.33) | 192.08 | 479.98 | (45.70) | (116.27) | (32.58) | (88.98) |
Capital Expenditures |
(138.23) | (130.92) | (133.63) | (158.84) | (119.55) | (107.63) | (155.22) | (122.94) | (76.70) | (64.79) |
Net Current Asset Value |
(331.55) | (298.23) | (280.14) | (1,036.55) | (791.56) | (599.03) | (975.01) | (892.41) | (795.27) | (793.33) |
EV/EBIT |
40.21 | 30.51 | 41.69 | 38.51 | 60.95 | 62.18 | 42.33 | 33.86 | 33.86 | 30.71 |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.05 | 0.04 | 0.04 | 0.06 | 0.06 | 0.04 | 0.04 |
Price to Operating Income |
40.01 | 30.22 | 41.47 | 37.78 | 60.19 | 61.42 | 40.68 | 32.89 | 33.53 | 30.13 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.18 | 0.16 | 0.17 | 0.18 | 0.17 | 0.16 | 0.19 | 0.22 | 0.22 |
Cash ROIC |
46.69% | 31.91% | 29.32% | 25.77% | 37.75% | 28.07% | 23.91% | 24.86% | 17.66% | 18.43% |
Accounts Receivable Turnover |
8.39 | 8.37 | 8.53 | 8.76 | 9.19 | 9.01 | 9.29 | 9.16 | 8.97 | 9.04 |
Accounts Payable Turnover |
14.64 | 13.51 | 13.32 | 12.04 | 13.91 | 15.48 | 14.70 | 14.24 | 13.72 | 14.20 |
Inventory Turnover |
4.33 | 3.98 | 3.93 | 4.28 | 5.54 | 5.61 | 5.65 | 5.76 | 5.41 | 4.61 |
Average Days of Payables |
24.51 | 27.45 | 27.45 | 29.52 | 31.97 | 23.96 | 25.30 | 26.12 | 28.04 | 27.40 |
Days of Inventory on Hand |
83.86 | 91.79 | 94.36 | 98.50 | 74.06 | 67.46 | 68.35 | 65.10 | 68.81 | 72.10 |
Average Receivables |
512.98 | 465.51 | 429.03 | 384.48 | 349.89 | 300.37 | 259.08 | 241.73 | 219.55 | 196.41 |
Average Payables |
112.31 | 112.43 | 110.43 | 113.18 | 95.35 | 73.37 | 70.85 | 68.25 | 63.51 | 56.35 |
Average Inventory |
379.82 | 381.08 | 374.05 | 318.43 | 239.45 | 202.45 | 184.16 | 168.81 | 161.18 | 173.43 |
Average Assets |
3,322.10 | 3,276.68 | 3,003.35 | 2,591.98 | 2,365.88 | 2,063.52 | 1,684.91 | 1,625.38 | 1,622.06 | 1,502.85 |
Average Common Equity |
1,600.35 | 1,539.92 | 1,046.63 | 649.36 | 661.39 | 405.31 | 84.30 | (31.54) | (81.03) | (96.10) |
Columns are period end dates · fundamentals updated 5 Nov 2026